Cat Stress Score (CSS) was significantly predicted by intake type and days in the study. by Allison Andrukonis (11846404)

Descriptive statistics (means) for full sample and by lockdown status. by Drew B. Cameron (10687420)

Subjects:

Pre and post-treatment mean EPG values on days 0, 7, 14, 21, and 28. by Sohail Afzal (10850709)

Subjects:

Reducing Dscam1 diversity decreases adult lifespan in an exon-specific manner, Related to Fig 3. by Haiyang Dong (4783608)

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

“…<b>(D)</b> Similarly, U251MG cells showed significantly decreased clonogenic potential upon 100ΜM SHG-44 treatment when compared to 100ΜM cis-platin and the untreated control. …”

General characteristics and clinical data of the subjects included in the study. by Spela Kokelj (8356644)

Subjects:

Distribution of average relative amounts of lipid classes. by Spela Kokelj (8356644)

Subjects:

Flow chart on the inclusion and drop out of patients. by Spela Kokelj (8356644)

Subjects:

Differentially abundant lipid species in COVID-19 cases at baseline and at follow-up as compared to healthy controls. by Spela Kokelj (8356644)

Subjects:

Symptoms reported by COVID-19 cases at baseline and at follow-up. by Spela Kokelj (8356644)

Subjects:

Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (sign... by Mobina Faqani (22783963)

Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “... by Mobina Faqani (22783963)

Column charts of SI_8min and SI_10min in the therapy and control group at follow-up. by Felix L. Herr (21544362)

Subjects:

Column charts of WiAUC in therapy and control group at baseline and follow-up. by Felix L. Herr (21544362)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Subjects:

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects: